Drug intelligence / Profile preview

gemcitabine + lipoplatin

Development stage: Unknown
Lead developer: Regulon
Modality: Small Molecules
Administration: Intravenous

Overview

Gemcitabine + lipoplatin is a chemotherapy combination consisting of gemcitabine and liposomal cisplatin (lipoplatin). Lipoplatin is a liposomal formulation of cisplatin designed to reduce toxicity while maintaining efficacy. This combination has been studied primarily for non-small cell lung cancer (NSCLC) and pancreatic cancer. Lipoplatin delivers cisplatin in a liposomal formulation that reduces nephrotoxicity, neurotoxicity, and myelotoxicity compared to conventional cisplatin. When combined with gemcitabine, this formulation has demonstrated efficacy comparable to or better than traditional cisplatin combinations with a significantly improved toxicity profile.

Other names: LipoGem

Targets

DNA polymerase familyRNR (Ribonucleotide reductase)DNA

Beyond the preview

Go deeper on gemcitabine + lipoplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gemcitabine + lipoplatin.

Explore the full profile